Checkpoint Therapeutics Inc., a subsidiary of Fortress Biotech Inc., has big plans. During September the company will launch a phase I/II trial of its third-generation EGFR inhibitor CK-101 in non-small-cell lung cancer and, around the same time, a public market listing.